Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies.

Authors:
Shamseddine A; Patel SH; Chavez V; Moore ZR; Adnan M and 13 more

Journal:
J Exp Med

Publication Year: 2022

DOI:
10.1084/jem.20220809

PMCID:
PMC9767651

PMID:
36534085

Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability sequencing data have been deposited under geo superseries gse218449 including bulk rna-seq for specific cardiac cell populations ( gse218447 ) and scrna-seq of cd45 + cells isolated from the heart ( gse218448 ). data availability sequencing data have been deposited under geo superseries gse218449"

Code Sharing
Evidence found in paper:

"Disclosures: J.E. Liu reported consulting for Pfizer and Caption Health, honoraria from Philips, and Data and Safety Monitoring Board for Caelum Biosciences. N.D. Socci reported grants from National Institutes of Health during the conduct of the study. S.F. Bakhoum reported personal fees from Volastra Therapeutics Inc. and Sanofi and other support from Cancer Research UK and Prostate Cancer Foundation outside the submitted work; in addition, S.F. Bakhoum has a patent for targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment licensed to Volastra Therapeutics Inc. and a patent for methods and strategies to target cytosolic dsDNA signaling in chromosomally unstable cancers pending. A.M. Schmitt reported spouse is an employee of Regeneron Pharmaceuticals. No other disclosures were reported."

Evidence found in paper:

"The study was supported by Department of Defense Discovery Award W81XWH1910002 (S.H. Patel, S.F. Bakhoum, A.M. Schmitt), National Institutes of Health R35 GM 124909 (A.M. Schmitt), a Memorial Sloan Kettering Cancer Center (MSKCC) Imaging and Radiation Sciences grant (S.H. Patel, S.F. Bakhoum, A.M. Schmitt), a MSKCC Chanel Endowment for Survivorship Research Grant (A.F. Yu), and MSKCC Cancer Center Support Grant P30 CA 008748. Author contributions: Conceptualization: S.H. Patel and A.M. Schmitt. Methodology: A. Shamseddine, S.H. Patel, Z.R. Moore, A.T. Chan, A.F. Yu, A. Piersigilli, N.D. Socci, S.F. Bakhoum, A.M. Schmitt. Investigation: A. Shamseddine, S.H. Patel, V. Chavez, Z.R. Moore, M. Adnan, M.D. Bona, J. Li, N.D. Socci, C.T. Dang, L.V. Ramanathan, K.C. Oeffinger, J.E. Liu, R.M. Steingart, A.F. Yu, A.M. Schmitt. Visualization: A. Shamseddine, S.H. Patel, Z.R. Moore, M.D. Bona, N.D. Socci. Funding acquisition: S.H. Patel, S.F. Bakhoum, A.F. Yu, A.M. Schmitt. Project administration: A.M. Schmitt. Supervision: S.F. Bakhoum and A.M. Schmitt. Writing – original draft: A. Shamseddine and A.M. Schmitt. Writing – review & editing: All authors."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025